



Título artículo / Títol article: Octodon degus: A Model for the Cognitive Impairment Associated with Alzheimer's Disease

Autores / Autors Tarragón Cros, Ernesto ; López, Dolores ; Estrada, Cristina ; Schenker, Esther ; Bordet, Regis ; Richardson, Jill C. ; Herrero Ezquerro, María Trinidad ; González Cuello, Ana

Revista: CNS neuroscience & therapeutics, 2013, vol. 19, no 9

Versión / Versió: Preprint del autor

Cita bibliográfica / Cita bibliogràfica (ISO 690): TARRAGON, Ernesto, et al. Octodon degus: A Model for the Cognitive Impairment Associated with Alzheimer's Disease. CNS neuroscience & therapeutics, 2013, vol. 19, no 9, p. 643-648

url Repositori UJI: <http://hdl.handle.net/10234/86849>

Octodon degus:
a model for the cognitive impairment associated with Alzheimer's Disease.

Ernesto Tarragon ^{a,b}, Dolores Lopez ^a, Cristina Estrada ^a, Esther Schenker ^c, Yves Lamberty ^d, Fabien Pifferi ^e, Regis Bordet ^f, Jill C. Richardson ^g, Maria-Trinidad Herrero ^{*a,b}

^a Clinical & Experimental Neuroscience (NiCE) and *Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)*, School of Medicine, University of Murcia, Campus Espinardo, 30100 Murcia, Spain; ^b School of Medicine, University Jaume I of Castellon, 12071 Castellon de la Plana, Spain; ^c Institut de Recherche Servier, 11 Rue du Moulineaux, 92150 Suresnes, France; ^d UCB Pharma s.a. Neuroscience Therapeutic Area, Chemin du Foriest, B-1420, Braine l'Alleud, Belgium; ^e UMR Centre National de la Recherche Scientifique/Museum National d'Histoire Naturelle 7179, Brunoy, France; ^f Department of Medical Pharmacology, Faculty of Medicine, University Lille-North of France, 1 Place Verdun, 59045 Lille, France; ^g GlaxoSmithKline, R&D China U.K. Group, Gunnels Wood Road, Stevenage, Herts, SG1 2NY, United Kingdom

Running title:

O. degus in the study of cognitive impairment

* Corresponding author:

María Trinidad Herrero Ezquerro, MD, PhD
Clinical and Experimental Neuroscience (NiCE-CIBERNED)
School of Medicine, Campus de Espinardo
University of Murcia 30100 Murcia, Spain
Tel. +34 868 88 46 83 / 84 84 Fax. +34 868 88 41 50
E-mail: mtherrer@um.es

Conflict statement: Authors report no conflict of interest in this work.

Abstract

Octodon degus (*O. degus*) is a diurnal rodent that spontaneously develops several physiopathological conditions, analogous in many cases to those experienced by humans. In light of this, *O. degus* has recently been identified as a very valuable animal model for research in several medical fields, especially those concerned with neurodegenerative diseases in which risk is associated with ageing. *O. degus* spontaneously develops β -amyloid deposits analogous to those observed in some cases of Alzheimer's disease (AD). Moreover, these deposits are thought to be the key feature for AD diagnosis, and one of the suggested causes of cell loss and cognitive deficit. This review aims to bring together information to support *O. degus* as a valuable model for the study of cerebral aging.

Keywords: Memory, Mild Cognitive Impairment, Alzheimer disease, *Octodon degus*, Amyloid beta-protein

Introduction

One of the major areas of interest in the field of neuroscience is the study of age-related brain pathologies. Understanding the origin of such pathologies, as well as how they progress through different cellular mechanisms and how this process finally affects cognitive and behavioral processes is essential for developing therapies and intervention strategies. Among the vast variety of brain pathologies, Alzheimer's disease (AD) deserves special attention. Being a neurodegenerative disease, the symptoms do not appear spontaneously, but, unlike in the case of a psychosis or amnesia, gradually. The pathology progresses relentlessly until the symptoms are manifest and the memory function, as well as other cognitive domains such as orientation, problem solving or even changes in personality, become apparent. In most cases, patients are no longer able to take care of themselves and require full-time care ¹.

Basic research in Alzheimer's disease

There are currently no approved disease-modifying treatments that are able to halt or slow down the pathology in AD or other common neurodegenerative disease. There are, however, vast ranges of different pharmacological and psychological therapies in development stages that aim to slow down the advance of functional loss. However, it is clear that we need to understand more about the cause of this disease and its natural progression if we are to understand when and how to treat it.

There are several approaches to the study of AD, including those based on cellular models ²⁻⁴. Nonetheless, although these models may be very useful for unraveling the molecular mechanisms that underlie the symptomatology, there is a great gap between the conclusions deduced from them and the clinical outcome that this disease displays. On the other hand, the use of animal species may contribute not only to understanding cellular and pathophysiological

characteristics of Alzheimer's, but also to reproduce the cognitive deficits shown in patients. In our mind, this could seem a more ecological and appropriate approach and one more suited for a better appreciation of the different features of the illness. In this sense, we could say that animal models are good for their capacity to imitate both pathophysiological conditions and behavioral outcome (if any). Therefore, it is fundamental for such models to be able to measure cognitive and behavioral function in an accurately and reliably way.

A number of animal models have been generated in an attempt to reproduce AD pathology. Most of these models have used rodents and there have been some promising advances ⁵⁻⁷. Several studies have demonstrated that Alzheimer pathology markers are absent in wild-type rodents, making it necessary to generate transgenic animals overexpressing human amyloid precursor protein (β -APP) harboring familial AD mutations ⁸⁻¹⁰ or to perform intracerebral injections of A β aggregates ^{11,12} to achieve homologous states of the disease.

Despite the wide range of animal models that are currently used in the study of behavioral and physiopathology features of AD ¹³, rodents are the most utilized. In the last decades, for instance, the number of transgenic models that have been developed has remarkably increased, widening the alternatives and targeting those characteristics that most significantly are identified within this neurodegenerative disease ¹⁴. As the A β cascade is the main hypothesis for the AD, the achievement of models that lead to the development of such characteristics is a milestone for the advance in understanding this pathology.

In this sense, following the A β hypothesis, transgenic models are mainly derived from different branches that over express three hallmarks identified as regard the AD: APP protein, presenilin 1 and 2, and tau protein ¹⁵, aiming to develop the characteristic amyloid accumulation and neurofibrillary tangles (NFTs) ¹⁶. The major advantage of these models is that they succeed in reproducing a similar pathophysiological and behavioral outcome that is observed among AD

patients^{17,18}. However, although transgenic models have proved their value for the study of AD, they raise important restrictions.

In the first place, to our view, the most important limitation these models present is the need for genetic and/or pharmacological manipulation to reach the inherent pathophysiological state of Alzheimer's. For instance, it is known that AD patients show a significant neuron loss¹⁹, and this feature has to be implanted in the mouse because even transgenic models show no such loss without manipulation²⁰. Another important similarity between human and rodent pathology that these models lack of, is the anatomical distribution of the senile plaques and NFT accumulation¹⁷. In humans, neuronal death derived from these two properties has been primarily located in the prefrontal and parietal cortices (mainly hippocampus)¹⁶. However, this allocation has not been achieved with the different models available. Taking this into account, the availability of a model that may cover these limitations would be undoubtedly appreciated.

In recent years, a rodent endogenous to Chile, the *Octodon degus* (*O. degus*) has gained prominence as a valued model for many different diseases, including those related with neurodegeneration, since this animal may develop naturally several symptoms that can be linked to a similar number of pathological conditions (Figure 1). Because of its particular diurnal cycle, it has frequently been used in circadian studies^{21,22}. It is also a highly social rodent, which explains its role in social and neuroaffective research^{23,24}. However, over the last few years, the participation of degus in the study of neurodegeneration has suggested that this area of research is the most promising application of this model. This diurnal cavimorph rodent lives up to 7 years average in captivity²⁵, making it *per se* an interesting model for use in longitudinal studies, including those related in the neuropsychobiology of ageing, and AD.

Octodon-Human A β aggregates similarities

Among the different hypotheses raised to explain the origin and evolution of AD, the most widely held is that which stresses the importance of cholinergic neurodegeneration and the appearance of two principal markers: the NFTs formed through the dysfunctional hyperphosphorylation of tau protein, and the deposition of A β aggregates, which are thought to be the trigger for neuronal death ²⁶. However, the relationship between these two elements is not clear, although several hypotheses have attempted to link them ^{26,27}.

A few years ago, Inestrosa and collaborators demonstrated that *O. degus* naturally develop characteristic histopathological hallmarks typical to those found in AD patients ²⁸. The discovery showed that this rodent, in its natural environment, might produce plaques in different brain areas ²⁹, including hippocampus and frontal cortex, both of which are severely affected in AD patients ¹⁶. Moreover, immunohistochemical and genetic analyses performed on the *O. degus* revealed a high degree of similarity between human deposits and the A β precursor protein (A β -PP). Also, RT-PCR analysis showed the *O. degus* and human A β peptide sequence to be 97.5% homologous ²⁸. This animal presents only one amino acid substitution with respect the human, which presents an advantage to other models (rats, for example, present in their A β sequence three amino acid substitution) (Figure 2). In this sense, differently to transgenic animals, there is no need to overexpress this human APP to generate significant levels of amyloid protein, which will help to avoid the overexpression of APP. This is an important question, since it has been postulated as to why there is a limited neuronal loss in the APP transgenic models, and is one of the main advantages of the *O. degus* as a model in preclinical research in AD.

Nevertheless, as promising as this animal might be, it still needs to satisfy certain requirements before it can be used as an appropriate model. In this sense, it is worth mentioning that the histopathological changes occurring in *O. degus* brains are only observed in aged animals ^{28,29}, and have never been detected in young animals so far. Similar comments may be made

regarding tau, which suggests that amyloid and tau deposition are age-dependent, as they are in AD patients^{30,31} and in some of the more successful transgenic mice studied to date¹⁰.

Another interesting analogy concerns the cholinergic system. The cerebral cortex of some human and non-human primates contains acetylcholine (AChE)-rich pyramidal neurons, which have been seen to decline in numbers during the progression of AD, a decrease claimed to be partly responsible for the memory deficits in Alzheimer patients^{15,19}. *O. degus* apparently shares the same AChE-rich neurons that are found in the cerebral cortex of adult humans. Moreover, the high degree of homology (97.5%) between the human and *O. degus* in A β sequence and the Tau structure, possibly triggered by the A β found in these animals, suggest that both play a major role in the appearance of AD markers in this rodent, including the presence of extra- and intracellular amyloid deposits and NFTs^{10,28,31}.

Octodon degus, what does it offer?

We have already mentioned the histological advantages that this model presents for AD research. However, without a cognitive counterpart, assessment of this model is not complete. As mentioned above, one of the key features of an animal model for AD should be its ability to mimic the cognitive and behavioral response in the different domains affected by this illness.

It has been recently demonstrated that the age-progressive accumulation of A β oligomers and phosphorylated tau proteins in *O. degus* from 12 to 36 months, negatively correlated with their performance in spatial and object recognition memory measured by two different behavioral paradigms: the Object Recognition Memory task and a spatial T-Maze. In this work, Ardiles et al. demonstrate that memory performance declines in an age-dependent manner, as aged animals committed less correct choices in the arms of the T-Maze and the time spent exploring the novel objects was significantly reduced in the object recognition task. Interestingly, the synaptic

strength in the old *O. degus* was reduced compared with the young ones, and the postsynaptic transmission was also impaired³².

As memory impairment is the first manifestation of AD symptoms and the most prominent of observable consequences, one of the requirements that *O. degus* should fulfill is that it should discriminate in different cognitive tests different memory deficits classically impaired in AD. Moreover, this should be achieved in response to the different challenges that are used to induce cognitive impairment, one of the most widespread of which is sleep deprivation.

Sleep deprivation (SD) has been widely documented as one of the challenges that most effectively induce transient cognitive impairment³³⁻³⁶ in animals³⁷⁻³⁹ and humans⁴⁰. SD has also been studied in the *O. degus*⁴¹ (Figure 3). This condition affects the formation, expression and retrieval of memories^{35,36}, and produces a deficient consolidation in both procedural and declarative memories^{33,42}. Evaluating memory impairment caused by this challenge in the *O. degus* is especially interesting, given their phase inversion capacity²². Sleep-wake deregulation is commonly seen in AD^{43,44}, and is displayed as agitation, disrupted sleep or breathing difficulties⁴³. Sleep studies performed on *O. degus* have demonstrated that, despite being diurnal, this animal is able to switch from diurnal to nocturnal phase behavior in a few days⁴⁵. Together with all the AD-like hallmarks displayed by this rodent, this chronobiological characteristic adds value to the *O. degus* as an attractive model of the cognitive decline and behavioral outcome observed in age-related neurodegenerative diseases, and also confirms SD as an appropriate methodological choice. With this method, researchers would be able to induce transitory memory deficits in both young and old animals to further compare the impact of such procedure and the effect of aging and histopathological hallmarks formation on the behavioral outcome.

The most noteworthy feature of AD is memory loss, but it is not the only one. Besides the well-known deficit in problem solving^{46,47} and spatial orientation^{47,48}, patients with Alzheimer's also

present a wide range of psychological affectations such as stress ⁴⁹ and anxiety ^{50,51}, as well as different systemic impairments ⁵². In this sense, it has been demonstrated that the *O. degus* may develop atherosclerosis, a pathological states frequently concomitant with AD ⁵³. It has been demonstrated that this rodent is able to develop an atherosclerosis condition directly derived from a rich-cholesterol diet, together with a lipoprotein metabolism similar to humans, being ⁵⁴. This, combined with the presence of hyperglycemia strongly correlates with the appearance of a type-2 diabetes ⁵⁵. Interestingly, aged *O. degus* also share with humans these pathological conditions ⁵⁴.

Despite the fact that many studies have shared inconsistent results concerning age-related changes in anxiety in different rodent models ^{56,57}, there is evidence of a significant age-related effect in *O. degus* (young and old adults) in the open field test and dark-and-light test, two widely validated procedures to assess anxiety in rodent models ⁵⁸. Popovic and collaborators explored the relationship between age and anxiety and demonstrated that, the older group spent less time in the center of the open field, compared with the young adult group ⁵⁹, and that the latter group were more willing to spend more time in the light than the older ones ⁵⁹, suggesting that anxiety may increase with age in these animals.

Another AD-like symptom that is apparent in the *O. degus* is related to their social life. It is known that in many cases of AD, patients tend to develop social problems mainly for two reasons: because of the dementia associated with the disorder ⁶⁰ and the stress causes to caregivers ^{61,62}. *O. degus* is generally described as a very social rodent with a highly complex social behavior ^{23,24}. However, as in AD, this animal is also subjected to problematic interactions with other members of its colony when stressful events occur ⁶³. In this sense, Poeggel and colleagues reported severe behavioral deficits and neural alterations in the frontal cortex ⁶⁴, which has also shown to be affected in AD patients ^{62,65}.

It is also common to find patients that have difficulty in manipulating complex objects, or performing fine motor movements^{66,67}. To date, the range of possibilities to test this particular deficit is scarce, and is mainly confined to non-human primates. However, to the best of our knowledge there is no literature covering manipulative and fine motor problems in rodents. Thus, it is worth mentioning that *O. degus* is the only rodent to date which has been demonstrated to be sensitive to training in object manipulation towards obtaining a reward⁶⁸. The authors of this work were able to train 5 animals to retrieve a food reward located in a platform that could only be reached using one of the different tools to which they were given access. Animals learned the task with the same efficiency as shown by non-human primates in similar conditions⁶⁹, demonstrating an increasingly understanding of tool usage, not only regarding the physical properties of the tool, but also its functional attributes⁶⁸.

Further directions

We have reviewed a range of studies performed with the *O. degus*, a diurnal rodent native to Chile. The main interest in this animal in the field of cognition is that it has recently been proposed as a putative model for AD, principally because it presents two of the major histopathological markers for this disorder (β -Amyloid plaques and neurofibrillary tangles containing hyperphosphorylated tau). Several reports have also suggested that cognitive impairment in *O. degus* may be compared with that observed in humans. Therefore, this animal could represent one of the most promising models for the study of cognitive impairment associated with AD impairment. Whilst investigation with *O. degus* in the field of cognitive sciences is still in its early stages, we believe that the degus provides an excellent opportunity for exploring the mechanisms underlying late developmental changes in the nervous system, and therefore, the behavioral and cognitive outcomes resulting from such changes.

Acknowledgements

The activity leading to the present review has received funding from: i) the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement n°115009 (Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development, PharmaCog), ii) EFPIA's kind contribution (www.imi.europa.eu), and iii) Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spanish Ministry of Economy and Innovation. We thank the staff of the University of Murcia for its help: Dr. Ana María Madariaga for her valuable comments, and M. Philip Thomas for language suggestions concerning the manuscript.

References

- [1] Haak, N, Peters M. Pilgrimages in Partnering with Palliative Care. *Alzheim Care Q* 2004 **5**: 300-12.
- [2] Moghekar A, Rao S, Li M, et al. Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro. *J Biol Chem* 2011; **286**: 15989-97.
- [3] Park SH, Kim JH, Bae SS, et al. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β -induced cognitive deficits associated with decreased amyloid β accumulation. *Biochem Biophys Res Commun* 2011; **408**: 602-08.
- [4] Leuner K, Schütt T, Kurz C, et al. Mitochondria-derived ROS lead to enhanced amyloid beta formation. *Antiox Redox Signal* 2012; **16**: 1421-33.
- [5] Asberom T, Zhao Z, Bara TA, et al. Discovery of gamma-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease. *Bioorg Med Chem Lett* 2007; **17**: 511–16.
- [6] Filali M, Lalonde R, Theriault P, Julien C, Calon F, Planel E. Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD). *Behav Brain Res* 2012; **234**: 334-42.
- [7] Howlett DR, Richardson JC. The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP? *Histol Histopathol* 2009; **24**: 83-100.
- [8] Chishti MA, Yang DS, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. *J Biol Chem* 2001; **276**: 21562–70.

- [9] Jawhar S, Wirths O, Schilling S, Graubner S, Demuth H-U, Bayer T. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Ab formation, induces behavioural deficits, and glutaminyl cyclase knock-out rescues the behavioural phenotype in 59FAD mice. *J Bio Chem* 2006; **286**: 4454–60.
- [10] Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A β and synaptic dysfunction. *Neuron* 2003; **39**: 409-21.
- [11] Gonzalo-Ruiz A, Pérez JL, Sanz JM, Geula C, Arévalo J. Effects of lipids and aging on the neurotoxicity and neuronal loss caused by intracerebral injections of the amyloid-beta peptide in the rat. *Exp Neurol* 2006; **197**: 41-55.
- [12] Stepanichev MY, Moiseeva YV, Lazareva NA, Onufriev MV, Gulyaeva NV. Single intracerebroventricular administration of amyloid-beta (25-35) peptide induces impairment in short-term rather than long-term memory in rats. *Brain Res Bull* 2003; **61**: 197-205.
- [13] Braidy N, Muñoz P, Palacios AG, et al. Recent rodent models for Alzheimer's disease: clinical implications and basic research. *J Neural Transm* 2012; **119**:173–95.
- [14] Hock Jr BJ, Lamb B. Transgenic mouse models of Alzheimer's disease. *Trends Genet* 2011; **17**: S7–12.
- [15] Small SA, Duff K. Linking A-beta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. *Neuron* 2008; **60**: 534-42.
- [16] Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. *Lancet* 2011; **377**: 1019-31.
- [17] Götz J, Streffer JR, David D, et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. *Mol Psychiatry* 2004; **9**: 664-83.

- [18] Romberg C, Mattson MP, Mughal MR, Bussey T, Saksida L. Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). *J Neurosci* 2011; **31**: 3500-07.
- [19] Esiri MM, Chance SA. Vulnerability to Alzheimer's pathology in neocortex: the roles of plasticity and columnar organization. *J Alzheimers Dis* 2006; **9**: 79-89.
- [20] Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A. Neuron loss in APP transgenic mice. *Nature* 1998; **395**:755-56.
- [21] Otolara BB, Vivanco P, Madariaga AM, Madrid JA, Rol MA. Internal temporal order in the circadian system of a dual-phasing rodent, the Octodon deguss. *Chronobiol Int* 2010; **27**: 1564-79.
- [22] Vivanco P, López-Espinoza A, Madariaga AM, Rol MA, Madrid JA. Nocturnalism induced by scheduled feeding in diurnal Octodon degus. *Chronobiol Int* 2010; **27**: 233-50.
- [23] Colonnello V, Iacobucci P, Fuchs T, Newberry RC, Panksepp J. Octodon degus. A useful animal model for social-affective neuroscience research: basic description of separation distress, social attachments and play. *Neurosci Biobehav Rev* 2010; **35**: 1854-63.
- [24] Seidel K, Poeggel G, Holetschka R, Helmeke C, Braun K. Paternal deprivation affects the development of corticotrophin-releasing factor-expressing neurones in prefrontal cortex, amygdala and hippocampus of the biparental Octodon degus. *J Neuroendocrinol* 2011; **23**: 1166-76.
- [25] Lee TM. Octodon degu: a diurnal, social, and long-lived rodent. *ILAR J* 2004; **45**: 14-24.
- [26] Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. *Behav Brain Res* 2011; **221**: 555-63.

- [27]Reyes AE, Chacoón MA, Dinamarca MC, Cerpa W, Morgan C, Inestrosa NC.
Acetylcholinesterase-A β complexes are more toxic than A β fibrils in rat hippocampus:
effect on rat β -amyloid aggregation, laminin expression, reactive astrocytosis and
neuronal cell loss. *Am J Pathol* 2004; **164**: 2163-74.
- [28]Inestrosa NC, Reyes AE, Chacón MA, et al. Human-like rodent amyloid-beta-peptide
determines Alzheimer pathology in aged wild-type *Octodon degu*. *Neurobiol Aging* 2005;
26: 1023-28.
- [29]van Groen T, Kadish I, Popović N, et al. Age-related brain pathology in *Octodon degu*:
blood vessel, white matter and Alzheimer-like pathology. *Neurobiol Aging* 2011; **32**:
1651-61.
- [30]Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev* 2001; **81**:
741-66.
- [31] Masters CL, Selkoe DJ. Biochemistry of Amyloid β -Protein and Amyloid Deposits in
Alzheimer Disease. *Cold Spring Harb Perspect Med* 2012; **2**: pp. a006262.
- [32]Ardiles AO, Tapia-Rojas CC, Mandal M, et al. Postsynaptic dysfunction is associated with
spatial and object recognition memory loss in a natural model of Alzheimer's disease.
Proc Natl Acad Sci USA 2012; **109**: 13835-40.
- [33]Jugovac D, Cavallero C. Twenty-Four Hours of Total Sleep Deprivation Selectively
Impairs Attentional Networks. *Exp Psychol* 2011; **1**: 1-9.
- [34]McEwen BS. Sleep deprivation as a neurobiologic and physiologic stressor: Allostasis
and allostatic load. *Metabolism* 2006; **55**: S20–3.
- [35]Huber R, Ghilardi MF, Massimini M, Tononi G. Local sleep and learning. *Nature* 2004;
430: 78–81.

- [36] Walker M, Stickgold P. Sleep-dependent learning and memory consolidation. *Neuron* 2004; **44**: 121-33.
- [37] Palchykova S, Crestani F, Meerlo P, Tobler I. Sleep deprivation and daily torpor impair object recognition in Djungarian hamsters. *Physiol Behav* 2006; **87**: 144-53.
- [38] Alhaider IA, Aleisa AM, Tran TT, Alkadhi KA. Sleep deprivation prevents stimulation-induced increases of levels of P-CREB and BDNF: protection by caffeine. *Mol Cell Neurosci* 2011; **46**: 742-51.
- [39] Alzoubi KH, Khabour OF, Rashid BA, Damaj IM, Salah HA. The neuroprotective effect of vitamin E on chronic sleep deprivation-induced memory impairment: the role of oxidative stress. *Behav Brain Res* 2012; **226**: 205-10.
- [40] Dodds CM, Bullmore ET, Henson RN, et al. Effects of donepezil on cognitive performance after sleep deprivation. *Hum Psychopharmacol* 2011; **26**: 578-87.
- [41] Kas MJ, Edgar DM. Circadian timed wakefulness at dawn opposes compensatory sleep responses after sleep deprivation in *Octodon degus*. *Sleep* 1999; **22**: 1045-53.
- [42] Mu Q, Nahas Z, Johnson K, et al. Decreased cortical response to verbal working memory following sleep deprivation. *Sleep* 2005; **28**: 55-67.
- [43] Bliwise DL. Sleep disorders in Alzheimer's disease and other dementias. *Clin Cornerstone* 2004; **6**, S16—28.
- [44] Srinivasan V, Kaur C, Pandi-Perumal S, Brown G, Cardinali D. Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value. *Int J Alzheimers Dis* 2011; 741974.

- [45] Vivanco P, Ortiz V, Rol MA, Madrid JA. Looking for the keys to diurnality downstream from the circadian clock: role of melatonin in a dual-phasing rodent, *Octodon degus*. *J Pineal Res* 2007; **42**: 280-90.
- [46] Sánchez-Benavides G, Gómez-Ansón B, Quintana M, et al. Problem-solving abilities and frontal lobe cortical thickness in healthy aging and mild cognitive impairment. *J Int Neuropsychol Soc* 2010; **16**: 836-45.
- [47] Jacobs HIL, Van Boxtel MPJ, Jolles J, Verhey FRJ, Uylings HBM. Parietal cortex matters in Alzheimer's disease: an overview of structural, functional and metabolic findings. *Neurosci Biobehav Rev* 2012; **36**: 297-309.
- [48] Laczó J, Andel R, Vyhnaek M, et al. Human analogue of the morris water maze for testing subjects at risk of Alzheimer's disease. *Neurodegener Dis* 2010; **7**: 148-52.
- [49] Stonnington CM, Locke DEC, Dueck AC, Caselli RJ. Anxiety affects cognition differently in healthy apolipoprotein E ϵ 4 homozygotes and non-carriers. *J Neuropsychiatry Clin Neurosci* 2011; **23**: 294-99.
- [50] Vloeberghs E, Van Dam D, Franck F, Staufenbiel M, De Deyn PP. Mood and male sexual behaviour in the APP23 model of Alzheimer's disease. *Behav Brain Res* 2007; **180**: 146-51.
- [51] Gallagher D, Coen R, Kilroy D, et al. Anxiety and behavioural disturbance as markers of prodromal Alzheimer's disease in patients with mild cognitive impairment. *Int J Geriatr Psychiatry* 2011; **26**: 166-72.
- [52] Silvestrini M, Viticchi G, Falsetti L, et al. The role of carotid atherosclerosis in Alzheimer's disease progression. *J Alzheimers Dis* 2011; **25**: 719-26.
- [53] Yarchoan M, Xie SX, Kling MA, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. *Brain* 2012; **135**: 3749-56.

- [54] Homan R, Hanselman JC, Bak-Mueller S, et al. Atherosclerosis in *Octodon degus* (degu) as a model for human disease. *Atherosclerosis* 2010; **212**: 48–54.
- [55] Fujisawa K, Katakami N, Kaneto H, et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. *Atherosclerosis* 2013; pii: S0021-9150(13)00051-8. DOI: 10.1016/j.atherosclerosis.2013.01.016.
- [56] Boguszewski P, Zagrodzka J. Emotional changes related to age in rats — a behavioral analysis. *Behav Brain Res* 2002; **133**: 323-32.
- [57] Torras-Garcia M, Costa-Miserachs D, Coll-Andreu M, Portell-Cortés I. Decreased anxiety levels related to aging. *Exp Brain Res* 2005; **164**: 177-84.
- [58] Ramos A. Animal models of anxiety: do I need multiple tests? *Trends Pharmacol Sci* 2008; **29**, 493-98.
- [59] Popović N, Baño-Otálora B, Rol MA, Caballero-Bleda M, Madrid JA, Popović M. Aging and time-of-day effects on anxiety in female *Octodon degus*. *Behav Brain Res* 2009; **200**: 117-21.
- [60] Wilks SE, Little KG, Gough HR, Spurlock WJ. Alzheimer's aggression: influences on caregiver coping and resilience. *J Gerontol Soc Work* 2011; **54**: 260-75.
- [61] Gonzalez EW, Polansky M, Lippa CF, Walker D, Feng D. Family caregivers at risk: who are they? *Issues Ment Health Nurs* 2011; **32**: 528-36.
- [62] Stubbs B. Displays of inappropriate sexual behaviour by patients with progressive cognitive impairment: the forgotten form of challenging behaviour? *J Psychiatr Ment Health Nurs* 2011; **18**: 602-07.
- [63] Helmeke C, Seidel K, Poeggel G, Bredy TW, Abraham A, Braun K. Paternal deprivation during infancy results in dendrite- and time-specific changes of dendritic development

- and spine formation in the orbitofrontal cortex of the biparental rodent *Octodon degus*. *Neuroscience* 2009; **163**, 790-98.
- [64] Poeggel G, Nowicki L, Braun K. Early social deprivation alters monoaminergic afferents in the orbital prefrontal cortex of *Octodon degus*. *Neuroscience* 2003; **116**: 617-20.
- [65] Shany-Ur T, Rankin KP. Personality and social cognition in neurodegenerative disease. *Curr Opin Neurol* 2011; **24**: 550-55.
- [66] Yan JH, Rountree S, Massman P, Doody RS, Li H. Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. *J Psychiatr Res* 2008; **42**: 1203-12.
- [67] Ameli M, Kemper F, Sarfeld AS, Kessler J, Fink GR, Nowak DA. Arbitrary visuo-motor mapping during object manipulation in mild cognitive impairment and Alzheimer's disease: a pilot study. *Clin Neurol Neurosurg* 2011; **113**: 453-58.
- [68] Okanoya K, Tokimoto N, Kumazawa N, Hihara S, Iriki A. Tool-use training in a species of rodent: the emergence of an optimal motor strategy and functional understanding. *PLoS ONE* 2008; **3**: e1860.
- [69] Ishibashi H, Hihara S, Iriki A. Acquisition and development of monkey tool-use: behavioral and kinematic analyses. *Can J Physiol Pharmacol* 2000; **78**: 958-66.
- [70] Brown C, Donnelly TM. Cataracts and reduced fertility in degus (*Octodon degus*). Contracts secondary to spontaneous diabetes mellitus. *Lab Anim (NY)* 2001; **30**: 25-6.
- [71] Ebensperger LA, Ramírez-Estrada J, León C, et al. Sociality, glucocorticoids and direct fitness in the communally rearing rodent, *Octodon degus*. *Horm Behav* 2011; **60**: 346-52.

Figure 1. Characteristics of *O. degus*. Brief description of several characteristics that naturally develop in the *O. degus* making it useful as an animal model in several fields. Numbers in brackets are for the correspondent reference in the bibliography.

Figure 2. Amino acid A β sequence. Differences and similarities between mice/rat, human and *O. degus* amino acid A β sequence. Differently from the mice/rat, the *O. degus* is only one amino acid different from the human sequence ^{28,29}.

Figure 3. Procedural scheme of the sleep deprivation induced by gentle handling. Adapted to the normal diurnal activity of the *O. degus*, sleep deprivation challenge starts at 7 p.m. in a 12/12-hour light and dark cycle. Gentle handling is a non-stressful way of preventing the animal from sleeping. After the procedure, the behavioral test takes place ⁴¹.

Figure 1




Figure 2




Figure 3

